| 1. |
中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會(CSCO)小細胞肺癌診療指南 2024. 北京: 人民衛生出版社, 2024.
|
| 2. |
Tomic K, Krpina K, Baticic L, et al. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report. J Drug Target, 2024, 32(5): 499-509.
|
| 3. |
Oser MG, Niederst MJ, Sequist LV, et al. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol, 2015, 16(4): e165-e172.
|
| 4. |
Jiang SY, Zhao J, Wang MZ, et al. Small-cell lung cancer transformation in patients with pulmonary adenocarcinoma: a case report and review of literature. Medicine (Baltimore), 2016, 95(6): e2752.
|
| 5. |
Liu Y. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: a case report and literatures review. Cancer Biol Ther, 2018, 19(6): 445-449.
|
| 6. |
Shi X, Duan H, Liu X, et al. Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors. Oncotarget, 2016, 7(23): 34240-34249.
|
| 7. |
Shaurova T, Zhang L, Goodrich DW, et al. Understanding lineage plasticity as a path to targeted therapy failure in EGFR-mutant non-small cell lung cancer. Front Genet, 2020, 11: 281.
|
| 8. |
Offin M, Chan JM, Tenet M, et al. Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes. J Thorac Oncol, 2019, 14(10): 1784-1793.
|
| 9. |
Rekhtman N, Tischfield SE, Febres-Aldana CA, et al. Chromothripsis-mediated small cell lung carcinoma. Cancer Discov, 2025, 15(1): 83-104.
|
| 10. |
Yin X, Li Y, Wang H, et al. Small cell lung cancer transformation: from pathogenesis to treatment. Semin Cancer Biol, 2022, 86(Pt 2): 595-606.
|
| 11. |
Li X, Luan X, Zhang M, et al. Potential therapeutic option for EGFR-mutant small cell lung cancer transformation: a case report and literature review. Front Immunol, 2024, 15: 1439033.
|
| 12. |
Marcoux N, Gettinger SN, O’Kane G, et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J Clin Oncol, 2019, 37(4): 278-285.
|
| 13. |
Ou SI, Lee TK, Young L, et al. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?. Lung Cancer, 2017, 106: 110-114.
|
| 14. |
Kuang L, Wang P, Zhou L, et al. Transformation of lung adenocarcinoma to small cell lung cancer following osimertinib treatment: a case report and literature review. Anticancer Drugs, 2025, 36(3): 253-259.
|
| 15. |
Liu J, Li X, Peng J. A Novel CAV1-MET fusion in SCLC transformation responds to crizotinib and osimertinib treatment. J Thorac Oncol, 2019, 14(6): e126-e128.
|
| 16. |
Lingling X, Maoxi C, Wei Y, et al. Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: a case report and literature review. Lung Cancer, 2023, 186: 107415.
|
| 17. |
Wang S, Xie T, Hao X, et al. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Thorac Cancer, 2021, 12(19): 2585-2593.
|
| 18. |
Wang W, Xu C, Chen H, et al. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: a multicenter retrospective study. Lung Cancer, 2021, 155: 20-27.
|
| 19. |
Suda K, Murakami I, Yu H, et al. Heterogeneity in immune marker expression after acquisition of resistance to EGFR kinase inhibitors: analysis of a case with small cell lung cancer transformation. J Thorac Oncol, 2017, 12(6): 1015-1020.
|
| 20. |
Zhang CY, Sun H, Su JW, et al. A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival. Lung Cancer, 2023, 175: 68-78.
|
| 21. |
Xu J, Xu L, Wang B, et al. Outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after EGFR tyrosine kinase inhibitors resistance: a systematic review and pooled analysis. Front Oncol, 2022, 11: 766148.
|
| 22. |
Lai L, Meng W, Wei J, et al. Transformation of NSCLC to SCLC after 1st- and 3rd-generation EGFR-TKI resistance and response to EP regimen and erlotinib: 2 CARE-compliant case reports. Medicine (Baltimore), 2021, 100(10): e25046.
|
| 23. |
Huang J, Zhang XH, Cai Y, et al. Rationale and design of a phase II trial of combined serplulimab and chemotherapy in patients with histologically transformed small cell lung cancer: a prospective, single-arm and multicentre study. Clin Oncol (R Coll Radiol), 2024, 36(1): 39-45.
|
